Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.47 |
| ▸ | BACE1 | P56817 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | CA12 | O43570 | 1/20 | 0.42 |
| ▸ | CA2 | P00918 | 1/20 | 0.42 |
| ▸ | CA7 | P43166 | 1/20 | 0.42 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.42 |
| ▸ | IDO1 | P14902 | 3/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | THRB | P10828 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | FABP1 | P07148 | 1/20 | 0.41 |
| ▸ | FABP6 | P51161 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8060763 | 0.85 | KCNH3 (0.44) | KDM4EHPGDKMT2AMEN1MAPT | |
| SCHEMBL8065424 | 0.85 | KDM4E (0.47) | KDM4EHPGDKMT2AMEN1MAPT | |
| SCHEMBL2115357 | 0.85 | HTT (0.50) | HSD17B10KDM4EHPGDHTTKMT2A | |
| SCHEMBL5846724 | 0.82 | MAOB (0.46) | BACE1CYP3A4 | |
| SCHEMBL8063033 | 0.81 | APP (0.48) | KMT2AMEN1MAPTAPP | |
| SCHEMBL7092633 | 0.81 | ALDH1A1 (0.33) | HSD17B10BACE1KDM4EKMT2ATHRB | |
| SCHEMBL7228990 | 0.81 | HTT (0.50) | HTTKMT2AMEN1MAPTPOLB | |
| SCHEMBL2454621 | 0.80 | L3MBTL1 (0.52) | TSHRHTTCA12CA2IDO1 | |
| SCHEMBL12473735 | 0.78 | HDAC8 (0.48) | TDP1 | |
| SCHEMBL5215530 | 0.78 | NOS1 (0.39) | TSHRHTTMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 134 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3259256-A1 | COMPOUNDS AND METHODS FOR INDUCING BROWNING OF WHITE ADIPOSE TISSUE | Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences (CN) | 2017-12-27 | — | — | EP | claimed |
| WO-2016131192-A1 | COMPOUNDS AND METHODS FOR INDUCING BROWNING OF WHITE ADIPOSE TISSUE | GUANGZHOU INSTITUTES OF BIOMEDICINE AND HEALTH, CHINESE ACADEMY OF SCIENCES (CN) | 2016-08-25 | — | — | WO | claimed |
| CN-102459166-B | Azetidinyl diamides as monoacylglycerol lipase inhibitors | JANSSEN PHARMACEUTICA NV | 2015-03-25 | — | — | CN | claimed |
| US-8962607-B2 | Azetidinyl diamides as monoacylglycerol lipase inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2015-02-24 | — | — | US | claimed |
| EP-2421823-B1 | AZETIDINYL DIAMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2015-01-14 | — | — | EP | claimed |
| US-20140243305-A1 | AZETIDINYL DIAMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS | JANSSEN PHARMACEUTICA NV (US) | 2014-08-28 | — | — | US | claimed |
| US-8445477-B2 | Azetidinyl diamides as monoacylglycerol lipase inhibitors | JANSSEN PHARMACEUTICA, NV (BE) | 2013-05-21 | — | — | US | claimed |
| US-8399454-B2 | Azetidinyl diamides as monoacylglycerol lipase inhibitors | JANSSEN PHARMACEUTICA, NV (BE) | 2013-03-19 | — | — | US | claimed |
| EP-2421823-A1 | AZETIDINYL DIAMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS | Janssen Pharmaceutica N.V. (BE) | 2012-02-29 | — | — | EP | claimed |
| EP-2421824-A1 | AZETIDINYL DIAMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS | Janssen Pharmaceutica N.V. (BE) | 2012-02-29 | — | — | EP | claimed |
| EP-1542686-A2 | ARYL SUBSTITUTED HYDANTOIN COMPOUNDS AND THEIR USE AS SODIUM CHANNEL BLOCKERS | Euro-Celtique S.A. (LU) | 2005-06-22 | — | — | EP | claimed |
| US-6903096-B2 | Quinazoline derivatives as medicaments | SCIOS, INC. (US) | 2005-06-07 | — | — | US | claimed |
| EP-1532119-A2 | ARYL SUBSTITUTED BENZIMIDAZOLES AND THEIR USE AS SODIUM CHANNEL BLOCKERS | Euro-Celtique S.A. (LU) | 2005-05-25 | — | — | EP | claimed |
| US-20040132777-A1 | Aryl substituted benzimidazoles and their use as sodium channel blockers | PURDUE PHARMA L.P. | 2004-07-08 | — | — | US | claimed |
| US-20040097569-A1 | Aryl substituted hydantoin compounds and their use as sodium channel blockers | EURO-CELTIQUE S.A. | 2004-05-20 | — | — | US | claimed |
| WO-2004011439-A2 | ARYL SUBSTITUTED BENZIMIDAZOLES AND THEIR USE AS SODIUM CHANNEL BLOCKERS | EURO-CELTIQUE S.A. (LU) | 2004-02-05 | — | — | WO | claimed |
| WO-2004010950-A2 | ARYL SUBSTITUTED HYDANTOIN COMPOUNDS AND THEIR USE AS SODIUM CHANNEL BLOCKERS | EURO-CELTIQUE S.A. (LU) | 2004-02-05 | — | — | WO | claimed |
| EP-1351686-A2 | SUBSTITUTED POLYCYCLIC ARYL AND HETEROARYL PYRIDINES USEFUL FOR SELECTIVE INHIBITION OF THE COAGULATION CASCADE | Pharmacia Corporation (US) | 2003-10-15 | — | — | EP | claimed |
| US-6476031-B1 | Quinazoline derivatives as medicaments | SCIOS, INC. | 2002-11-05 | — | — | US | claimed |
| WO-2002042272-A2 | SUBSTITUTED POLYCYCLIC ARYL AND HETEROARYL PYRIDINES USEFUL FOR SELECTIVE INHIBITION OF THE COAGULATION CASCADE | PHARMACIA CORPORATION (US) | 2002-05-30 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140243305-A1 | AZETIDINYL DIAMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS | PNLIP, LPL, LIPA | HSD17B10 179/4885BACE1 1751/4885KDM4E 1931/4885 |
| US-20040097569-A1 | Aryl substituted hydantoin compounds and their use as sodium channel blockers | SCN1A, CACNA1S, SCN1B | HSD17B10 1607/4885BACE1 988/4885KDM4E 3550/4885 |
| US-20040132777-A1 | Aryl substituted benzimidazoles and their use as sodium channel blockers | CACNA1S, CACNA1I, SCN1A | HSD17B10 2041/4885BACE1 957/4885KDM4E 2526/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.